Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Newron Pharmaceuticals SpA

NWRN.S ✓ COMPLIANTFree checks used up today ☆ Track — members

Europe · Healthcare · Biotechnology & Medical Research ·

Switzerland Micro Cap Analyst: BUY

Last Close

$10.58

▲ +2.12%

Market Cap $223.62M · Vol 60.07K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$223.62M

Micro Cap

Div Yield

N/A

Annual dividend

EPS Growth

-116.52%

YoY

RSI (14)

57.04

Momentum

Beta

1.48

vs Market

52W High

$38.82

74.19% below

52W Low

$6.97

49.86% above

Volume

60.07K

Avg 102.02K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

87.16%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Newron Pharmaceuticals SpA (NWRN.S) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does NWRN.S pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+5.98%

-21.52%

-28.26%

-47.07%

YTD

-63.61%

-38.79%

+107.14%

+355.88%

Financials & Valuation

TTM · Annual

Total Revenue	$22.46M
Net Income	$-15,549,135.00
Revenue Growth (YoY)	-84.94%
Gross Margin	88.99%
Operating Margin	-24.47%
Net Profit Margin	-69.22%
ROE	N/A
ROA · ROIC	-23.77% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	26.75
P/B	N/A
P/FCF	15.84
EPS Growth	-116.52%
Outstanding Shares	21.24M

Technical Indicators

50-Day SMA	$12.64
200-Day SMA	$17.49
RSI (14)	57.04
Beta	1.48
52-Week High	$38.82
52-Week Low	$6.97

Volume Today	60.07K
Avg Daily Volume (30D)	102.02K
Relative Volume	0.59x
Volatility (10D)	68.22
Volatility (30D)	105.78
Free Float	87.16%

Analyst Consensus

BUY

Current Price $10.58

Mean Target $40.24

52W Low$6.97 52W High$38.82

Current

Target

$6.97 $38.82

Current Analyst target

+280.38% upside potential · 6 analysts

Identifiers

ExchangeEurope

FIGIBBG001SKJG51

ISINIT0004147952

CountryItaly

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateMar 24, 2027

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +0.74% ONC BeOne Medicines AG -1.08% 068270.KS Celltrion, Inc. -1.67% MEDP Medpace Holdings, Inc. -1.29% CRL Charles River Laboratories International, Inc. -1.51%

Company Profile

Newron Pharmaceuticals SpA is an Italy-based company operating in the medical research sector. It is a biopharmaceutical company focused on the research, development, and commercialization of therapies for disorders of the central and peripheral nervous system (CNS). The Company specializes in neurological and psychiatric diseases, including schizophrenia and Parkinson’s disease. Its activities include drug discovery, clinical development, regulatory approval processes, and strategic licensing and commercialization partnerships with pharmaceutical companies worldwide. The Company has built a pipeline comprised of drug candidates at different clinical stages and has a proven track record of drug development and commercialization, such as evenamide, safinamide and ralfinamide. Newron Pharmaceuticals SpA operates at global level.